Gemma Biotherapeutics ("GEMMABio"), a clinical‑stage, global, genetic medicines company, today announced the presentation of preclinical data supporting candidate declaration for GB703, a novel, ...

Regenxbio announces positive results from pivotal phase III AFFINITY DUCHENNE study of RGX-202 to treat Duchenne muscular dystrophy: Rockville, Maryland Friday, May 15, 2026, 14:0 ...

Regenxbio’s gene therapy for Duchenne muscular dystrophy has smashed the primary endpoint of its pivotal trial, securing a win for a biotech that has struggled in recent months under the weight of a ...

An 11-year-old Philadelphia student with Duchenne muscular dystrophy has been forced to climb stairs for weeks due to a ...

Regenxbio said its experimental gene therapy for Duchenne muscular dystrophy succeeded in a trial, paving the way for a ...

Regenxbio said top-line results showed it met its primary endpoint in a Phase 3 study of its RGX-202 gene therapy for Duchenne Muscular Dystrophy. The trial met its primary endpoint with high ...

REGENXBIO Inc. RGNX on Thursday released topline and interim functional data from the pivotal Phase 1/2/3 AFFINITY DUCHENNE ...

Add Yahoo as a preferred source to see more of our stories on Google. When Conner Curran was first diagnosed with Duchenne muscular dystrophy at age 4, his parents were told there was nothing they ...

Duchenne muscular dystrophy (DMD) is a genetic condition that causes increasing muscle weakness over time. While DMD currently has no cure, researchers are studying potential new treatments. When ...

CNW/ - Families, friends, and supporters from coast to coast to coast are walking, running, and rolling this May, in support ...

Doctors at a Delhi-NCR hospital have treated what the hospital claimed could be the worlds first reported case of testicular ...

Shares of REGENXBIO declined 37% on a mixed data readout and other updates from the company's first quarter earnings call Thursday.